RxDoctor Payments Data

Joseph Grubbs

Ophthalmology · Richmond, VANPI 1033538749

Payments from drug & device makers

$1,570in general payments, 2019–2025

Across 64 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Notal Vision, Inc.$375
  • Ocular Therapeutix, Inc.$229
  • Rxsight Inc$175
  • Alcon$155
  • AbbVie$150
  • Aerie Pharmaceuticals, Inc.$137
  • plus $349 from 11 others

What the payments were for

  • Food & beverage$1,210100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,570 in reported general payments places this provider in the 55th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$570,907
Medicare patients
1,675
Services billed
4,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost45$22,532
RocklatanNetarsudil Mesylat/Latanoprost31$10,296
Latanoprost724$8,163
Timolol Maleate183$8,083
Prednisolone Acetate205$5,760
Brimonidine Tartrate46$5,112
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat70$1,468
MoxifloxacinMoxifloxacin Hcl52$1,145
Dorzolamide Hcl71$1,059
Ketorolac Tromethamine31$637
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha44$584
ErythromycinErythromycin Base20$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$150$22,53245 claims
Aerie Pharmaceuticals, Inc.Rocklatan$137$10,29631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →